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OBSERVATIONS
Glial Cell
Line–Derived
Neurotrophic Factor
in the Vitreous of
Patients With
Proliferative
Diabetic Retinopathy
G lial cell line–derived neurotrophicfactor (GDNF) belongs to the neu-rotrophic factor family. GDNF
functions are not restricted to neurons but
are also implicated in glial cell develop-
ment (1). We observed high expression
levels of GDNF receptor family -compo-
nent 2 (GFR2) in epiretinal membranes
(ERMs) in proliferative diabetic retinopa-
thy (PDR), indicating the involvement of
GFR2 in ERM formation in PDR (2).
Here, we examined the vitreous of pa-
tients with PDR for the presence of GDNF.
We assayed GDNF levels in vitreous
and serum samples from 75 consecutive
patients with PDR (54 patients) and mac-
ular hole (nondiabetic control subjects,
21 patients) who underwent vitrectomy.
PDR was classified as active (33 patients)
when there were perfused, multibranch-
ing iridic or preretinal capillaries and as
quiescent (21 patients) when only large
vessel or fibrosis was present. Informed
consent was obtained from each patient.
Undiluted vitreous samples were ob-
tained during the vitrectomy before in-
traocular infusion. Enzyme-linked
immunosorbent assay was performed to
determine GDNF level using a commer-
cially available immunoassay kit (Pro-
mega, Madison, WI). Mann-Whitney U
test was used to compare GDNF levels.
GDNF was undetectable in all the se-
rum samples examined. Intravitreous
GDNF level was significantly higher in the
PDR patients (means  SD: 156.1 
221.0 pg/ml) than in the control subjects
(26.5  53.2 pg/ml) (P  0.0042). Intra-
vitreous GDNF level was significantly
higher in active PDR (206.0  250.7 pg/
ml) than in quiescent PDR (77.7  135.5
pg/ml) (P  0.0388).
Glial cells are one of the main compo-
nents of ERMs. Our previous study (2)
showed that GFR2 mRNA expression
level is significantly higher in PDR ERMs
than in idiopathic ERMs, and this high
expression level is specific for GFR2
among neurotrophin receptors. GFR2
protein is detected in the glial component
of PDR ERMs. These results suggest that
GDNF is involved in the formation of the
glial cell component of PDR ERMs. Re-
sults of the present study support this
suggestion. Because GDNF increases ba-
sic fibroblast growth factor (bFGF) pro-
duction in Müller cells (3), released bFGF
may stimulate endothelial proliferation.
In this study, GDNF was undetect-
able in the serum samples. It is suggested
that the increased level of vitreous GDNF
in PDR reflects intraocular GDNF pro-
duction but not breakdown of the blood-
retina barrier.
In conclusion, intravitreous GDNF
level increased in PDR and was associated
with the activity of PDR. These results
suggest that GDNF is involved in the
pathogenesis of PDR.
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Concordance
Between the 2005
International
Diabetes Federation
Definition for
Diagnosing
Metabolic Syndrome
With the National
Cholesterol
Education Program
Adult Treatment
Panel III and the
World Health
Organization
Definitions
R ecently, the International DiabetesFederation (IDF) consensus (1)proposed a new definition for diag-
nosing metabolic syndrome. The new IDF
definition includes a lower waist circum-
ference than the National Cholesterol Ed-
ucation Program Adult Treatment Panel
III (ATP III) criteria (2) for diagnosing ab-
dominal obesity.
Since the most frequently used defi-
nitions for metabolic syndrome involve
different criteria for diagnosis of obesity,
and because differences in the prevalence
of metabolic syndrome seem to reproduce
differences in the prevalence of adiposity
(3), we determined the concordance be-
tween the 2005 IDF definition for meta-
bolic syndrome with the ATP III and
World Health Organization (WHO) (4)
definitions in a population from northern
Mexico.
This is a report of a population-based
study of apparently healthy men and non-
pregnant women aged 30–64 years from
Durango City in northern Mexico who
were selected through a randomized two-
stage cluster sampling procedure.
The cutoff value we used for abdom-
inal obesity was recommended for the
IDF consensus for ethnic South and Cen-
tral Americans (90 cm in men and 80
cm in women) and corresponds to the up-
per quartile in our population. To assess
the degree of agreement between different
metabolic syndrome definitions, we used
the weighted  test.
A total of 472 (67.4%) women and
228 (32.6%) men were studied. The
mean age was 44.7  11.8 years, and
the mean BMI was 29.1  5.3 kg/m2.
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The prevalence of metabolic syndrome
was 22.3, 22.6, and 15.4% according to
the IDF, ATP III, and WHO definitions,
respectively.
The IDF definition failed to detect
7.6% of ATP III patients with metabolic
syndrome, whereas 5.2% of the partici-
pants who were classified as normal by
the ATP III definition had metabolic syn-
drome according to IDF criteria (sensitiv-
ity and specificity of 92.4 and 94.8%).
The  statistic for the agreement between
IDF and ATP III definitions was 0.873.
The IDF definition failed to detect
15.7% of the WHO subjects with meta-
bolic syndrome, whereas 26.8% of the
participants who were classified as nor-
mal by the WHO definition had metabolic
syndrome by IDF criteria (sensitivity and
specificity of 84.3 and 73.1%). The  sta-
tistic for the agreement between the IDF
and WHO definition was 0.511.
The IDF criteria detected a higher
prevalence of obesity (33.7%) than the
ATP III and WHO criteria (23.7 and
22.6%, respectively). The WHO defini-
tion detected significantly fewer subjects
with high blood pressure (5.7 vs. 12.3%
of ATP III and IDF definitions) and low
HDL cholesterol (22.9 vs. 34.1% of ATP
III and IDF criteria). The prevalence of
hyperglycemia and hypertriglyceridemia
was 26.0 and 22.4%.
The lower cutoff point for abdominal
obesity, according to the IDF definition,
included 53.6 and 7.1% of the overweight
and lean subjects (according to BMI) in
the sample. Therefore, lowering the cutoff
for abdominal obesity has the benefit of
an early recognition of subjects at risk and
the possibility of early lifestyle intervention.
In the population from northern
Mexico, the IDF definition for metabolic
syndrome has a high concordance with
the ATP III definition, identifying similar
proportions of subjects with metabolic
syndrome and a low concordance with
the WHO definition.
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Determinants of
Response to Insulin
Therapy Following
Failure of Oral
Agents in Type 2
Diabetes
Obesity, ethnicity, and concomitantmetformin therapy may modify themetabolic response to insulin in pa-
tients with type 2 diabetes (1–3). We per-
formed a retrospective case note analysis
of 280 type 2 diabetic patients who had
failed oral drug therapy, defined as HbA1c
(A1C) 7.5% for at least 6 months de-
spite maximum doses of sulfonylurea and
metformin, and received treatment with
exogenous insulin for at least 12 months
for indications other than pregnancy,
acute coronary syndrome, stroke, sepsis,
or renal failure. Main outcome measures
were A1C, body weight, and daily insulin
dose. For the purpose of analysis, patients
with BMI below and above the median for
the whole cohort (28.2 kg/m2) were
termed nonobese and obese, respectively.
Following 12 months of insulin, overall
mean (95% CI) A1C fell 2.2% (1.9–2.6),
and weight gain increased by 6.0 kg (5.4–
6.6). A1C reduction was similar in both
the obese and nonobese groups. Concom-
itant metformin ameliorated weight gain
in the nonobese patients (5.1 [3.8–6.4]
vs. 7.4 kg [6.4–8.4], P  0.01) and re-
duced daily insulin requirements in the
obese (0.59 [0.53–0.65] vs. 0.77 units 
kg1  day1 [0.69–0.85], P  0.001) for
equivalent reductions in A1C.
Africans and Caribbeans benefited
from a greater reduction in A1C (2.7%
[2.2–3.2]) than Caucasians (2.1% [1.8–
2.4]) and Asians (1.6% [1.3–2.0]) (P 
0.01) despite smaller insulin require-
ments (African/Caribbeans 0.53 [0.48–
0.57], Caucasians 0.64 [0.60–0.69], and
Asians 0.67 units  kg1  day1 [0.56–
0.77], P  0.007). Concomitant met-
formin use was similar across all ethnic
groups. Weight gain was greater in Afri-
can/Caribbeans (7.1 [6.2–8.0]) than Cau-
casians (5.6 [4.7–6.4]) and Asians (4.8 kg
[3.3–6.4], P  0.01. Our observation, at
variance with a previous study (1), indi-
cates that baseline BMI does not affect the
benefit of insulin treatment on metabolic
control in type 2 diabetic patients but that
obese type 2 diabetic patients require
more insulin to overcome their greater in-
sulin resistance. Weight gain is virtually
an obligate consequence of insulin thera-
py–induced glycemic improvement in
patients who have failed oral agents, but
this is modulated by concomitant met-
formin treatment, degree of obesity, and
ethnicity. Moreover, metformin reduced
the requirement of insulin in obese type 2
diabetic patients for equivalent glycemic
amelioration, an effect that may mitigate
further weight gain.
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Kremezin (AST-120)
Delays the
Progression of
Diabetic
Nephropathy in
Japanese Type 2
Diabetic Patients
S trict control of blood glucose andblood pressure levels sometimes failto delay the development of diabetic
nephropathy, and effective therapy for di-
abetic nephropathy is not yet available.
AST-120, a spherical adsorptive carbon
preparation, absorbs uremic toxins, such
as indoxyl sulfate, in the gut. Since in-
doxyl sulfate can generate profibrotic cy-
tokines, the accumulation of uremic
toxins is toxic to the kidney. The removal
of indoxyl sulfate by the adsorptive car-
bon should be renoprotective (1). AST-
120 decreases circulating indoxyl sulfate
in patients with chronic kidney diseases
(2). In a nonrandomized study, we sought
to determine whether AST-120 can delay
the progression of diabetic nephropathy.
We explained the clinical usefulness
of AST-120 for diabetic nephropathy to
type 2 diabetic outpatients who also had
overt proteinuria with increased serum
creatinine levels (1.3 mg/dl), and 2.0 g
AST-120 was administered three times a
day between meals to those choosing to
receive it. Serum creatinine and blood
pressure levels were measured every
month for 6 months. In control subjects
not taking AST-120 (n  12), serum cre-
atinine levels significantly increased (be-
fore 2.50  0.26 mg/dl, after 6 months
3.27  0.34 mg/dl, P  0.005). In con-
trast, serum creatinine levels were not
changed in AST-120 –treated patients
(n  9) (before 2.63  0.36 mg/dl, after 6
months 2.40  0.20 mg/dl, NS). The
1/serum creatinine slope was significantly
(P  0.01) higher in AST-120–treated
subjects (0.0043  0.0036 dl  mg1 
week1) than in control subjects
(0.0174  0.0043 dl  mg1  week1).
AST-120 did not affect HbA1c levels (con-
trol subjects: before 7.4  0.2%, after 6
months 7.5  0.2%, NS, vs. AST-120–
treated subjects: before 7.0  0.4%, after
6 months 6.8  0.4%; NS) or systolic and
diastolic blood pressure levels (control
subjects: before 136.4  4.9/67.0  4.4
mmHg, after 6 months 136.1  3.6/
70.9  1.9 mmHg, NS, vs. AST-120–
treated subjects: before 131.5  4.3/
63.8  5.5 mmHg, after 6 months
130.3  2.5/69.8  3.0 mmHg, NS).
Since AST-120 in the gut did not ad-
sorb creatinine in the blood, and there is
no exchange of serum creatinine levels
between the gut and blood (3), the ob-
served attenuation of increase of serum
creatinine levels by AST-120 should not
be attributable to the excretion of creati-
nine into the feces. Although the results
are limited because of the nonrandomized
self-selection study design, our findings
indicate that AST-120 should contribute
to the delay of the development of renal
dysfunction in type 2 diabetic patients.
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Sex Differences of
Age-Dependent
Changes of Insulin
Sensitivity in
Japanese
Nondiabetic Subjects
Impaired insulin sensitivity is associ-ated with type 2 diabetes, hyperten-sion, and atherosclerosis . This
abnormality occurs by various causes
such as genetic background, obesity,
high-calorie diet, and low physical activ-
ity. Sex hormones also influence insulin
sensitivity, which might be a cause for sex
differences of the development of diabe-
tes, hypertension, and atherosclerosis
(1,2). Collectively, however, there is no
population-based study of sex differences
in insulin sensitivity. Here, we aimed to
determine whether there are sex and age
differences of insulin sensitivity and insu-
lin secretory activity in middle-aged non-
diabetic subjects.
Of 1,934 Japanese subjects who vis-
ited the Kinki Central Hospital between
April and October 2003 for their health
examinations, we evaluated 1,395 sub-
jects (854 men and 541 women) after
exclusion of subjects with diabetes, ma-
lignant diseases, chronic or acute inflam-
matory diseases, elevated serum creatinine
levels (106 mol/l), autoimmune disor-
ders, or subjects aged 40 years or 61
years.
Glucose tolerance status, homeostasis
model assessment (HOMA) determinants
(3), and BMI stratified by sex and age-
groups (40 – 49 and 50 –59 years) are
shown in Table 1. Prevalence of impaired
glucose tolerance was significantly higher
in men than in women of both age-
groups. In the 41–50 age-group, the in-
dex for insulin sensitivity (HOMA-%S)
was higher in women than in men,
whereas in the 51–60 age-group, there
was no sex difference. The index for pan-
creatic 	-cell function (HOMA-%	) was
not different between men and women of
both age-groups. BMI was lower in
women than in men of both age-groups.
In women, HOMA-%S was significantly
Letters
2590 DIABETES CARE, VOLUME 28, NUMBER 10, OCTOBER 2005
higher in the 41–50 age-group than in
51–60 age-group (P  0.0275), whereas
in men it was lower in the 41–50 age-
group than in the 51–60 age-group (P 
0.0348).
We found that there were sex differ-
ences of age-dependent changes of insu-
lin sensitivity, but not of insulin secretory
activity, in Japanese nondiabetic subjects.
Serum sex hormone levels differ between
men and women, and in women, serum
estrogens rapidly fall after menopause oc-
curring around age 50. Therefore, sex
hormones may be involved in the sex dif-
ferences of age-dependent changes of in-
sulin sensitivity. It has been reported that
postmenopausal hormone replacement
therapy lowered fasting glucose and insu-
lin levels in nondiabetic women (4) and
improved glycemic control in type 2 dia-
betic women (5), although disparate re-
sults have also been shown (6,7). In men,
serum testosterone levels have been
shown to be inversely related to serum
insulin level and BMI (8). In addition, it
has been shown that androgens decreased
the insulin-sensitizing adipocyte-derived
protein adiponectin (9). Thus, as a whole,
estrogens may have favorable effects on
insulin sensitivity, whereas androgens
may have undesirable effects on it.
In summary, insulin sensitivity de-
pends on sex and age. Insulin sensitivity is
higher in women than in men until age
50, but it falls to levels similar to men after
age 50. Therapeutic strategies for elimi-
nating insulin resistance for the preven-
tion of diabetes and atherosclerosis
should be classified by sex and age.
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Pietilä T, Virkamäki A, Hovatta O, Yki-
Järvinen H: Effect of estrogen replacement
therapy on insulin sensitivity of glucose
metabolism and preresistance and resis-
tance vessel function in healthy post-
menopausal women. J Clin Endocrinol
Metab 85:4663–4670, 2000
8. Phillips GB, Jing T, Heymsfield SB: Rela-
tionships in men of sex hormones, insu-
lin, adiposity, and risk factors for
myocardialinfarction.Metabolism52:784–
790, 2003
9. Nishizawa H, Shimomura I, Kishida K,
Maeda N, Kuriyama H, Nagaretani H,
Matsuda M, Kondo H, Furuyama N,
Kihara S, Nakamura T, Tochino Y, Fu-
nahashi T, Matsuzawa Y: Androgens
decrease plasma adiponectin, an insulin-
sensitizing adipocyte-derived protein. Di-
abetes 51:2734–2741, 2002
Isolated Bibrachial
Plexopathy in a
Patient With Type 2
Diabetes
D iabetic amyotrophy is typically alumbosacral radiculoplexus neu-ropathy resulting in weakness,
muscle wasting, and pain (1). Brachial
plexus involvement has been occasionally
described with lumbosacral radiculo-
plexus neuropathy (2–6), but isolated di-
abetic brachial plexopathy has been
described only in a patient with diabetic
ketoacidosis (7). We describe a patient
with well-controlled type 2 diabetes who
developed isolated bibrachial diabetic
plexopathy.
A 56-year-old African-American man
with a 13-year history of well-controlled
diabetes (total glycohemoglobin 6.2%,
normal 3.9–6.3%), on insulin for 5 years
and having no other major medical ill-
ness, developed left shoulder pain that ex-
tended to the hand over a few weeks and
right shoulder, extending into the right
hand 3 months later.
Pain was dull with intermittent shoot-
ing and sharp pains. He denied sensory
symptoms in the arms. Progressive left
arm weakness evolved 3 months after
the onset of pain and stabilized thereafter.
Table 1—Glucose tolerance status, HOMA-%S, HOMA-%, and BMI in 1,395 Japanese non-
diabetic subjects
Men Women P value*
41–50 age-group
n 378 183
Glucose tolerance status
(NGT/IGT) 296/82 161/22 0.0054
HOMA-%S (%) 122  60 150  69 0.0001
HOMA-%	 (%) 77  24 73  20 0.0670
BMI (kg/m2) 24.0  2.8 22.3  2.9 0.0001
51–60 age-group
n 476 358
Glucose tolerance status
(NGT/IGT) 321/155 290/68 0.0001
HOMA-%S (%) 132  73 138  57 0.1687
HOMA-%	 (%) 72  25 71  19 0.6670
BMI (kg/m2) 23.9  2.6 23.1  2.9 0.0001
Data are n or means  SD. *By Student’s t test or Fisher’s exact test. IGT, impaired glucose tolerance; NGT,
normal glucose tolerance.
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Right arm weakness developed over the
preceding 3 months and has continued to
progress. He denied leg symptoms. He re-
ported a 60-lb weight loss in the preced-
ing year. Examination revealed strength
as follows: MRC (Medical Research Coun-
cil) grade 1–5 (3 in bilateral deltoid and
biceps; 5 in right triceps, bilateral finger
abduction, and right finger extension;
and 4 in left triceps, bilateral wrist exten-
sion, and left finger extension). Strength
was normal in the legs. Reflexes were ab-
sent in bilateral brachioradialis and bi-
ceps muscles but were normal in other
areas. Babinski’s sign was absent.
Electromyography and nerve con-
duction studies revealed bilateral upper-
trunk brachial plexopathy; fibrillation
potentials in upper-trunk innvervated
muscles (biceps, deltoid, infraspinatus,
and brachioradialis); and sparing of tri-
ceps, pronator teres, first dorsal interro-
seus and abductor pollicis brevis, and
cervical paraspinal muscles. Radial, ulnar,
and median sensory nerve action poten-
tial amplitudes were reduced. (Only the
reduction in median sensory nerve action
potentials could be accounted for by me-
dian nerve entrapment at the wrist.)
Despite treatment with prednisone,
gabapentin, and narcotics, pain and
weakness are still prominent 2 years after
initiation of symptoms. However, the pa-
tient’s weight increased to baseline.
Brachial plexopathy in this patient
was likely related to his diabetes because
there was no other obvious etiology; pain
and weakness were prominent with rela-
tive paucity of sensory symptoms, and
there was preceding weight loss, both
characteristic features of lumbosacral ra-
diculoplexus neuropathy.
In conclusion, isolated lumbosacral
radiculoplexus neuropathy can occur as
the initial complication of diabetes, even
with good glycemic control. Thus, it is
likely due to microvasculitis-causing
nerve infarction rather than metabolic ab-
normalities in diabetes (1). Efficacy of im-
munosuppressive treatments is unproven
and is being evaluated in clinical trials.
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Proposal for the
Reconsideration of
the Definition of
Gestational Diabetes
In 1997, the American Diabetes Associ-ation (ADA) announced a new diag-nostic criterion for diabetes and set the
definition of gestational diabetes mellitus
(GDM). Before 1991, GDM was defined
as “a transient abnormality of glucose tol-
erance during pregnancy” (2–4). How-
ever, the 1997 definition of GDM by the
ADA includes diabetes diagnosed during
pregnancy. This definition ignores the
added risks to the mother and to the fetus
when the mother has undiagnosed type 2
diabetes. We propose reconsideration of
the definition, which would separate dia-
betes and slight abnormal carbohydrate,
so-called GDM, to provide a better model
of care for type 2 diabetic pregnant
women.
There are three problems concerning
an undiagnosed type 2 diabetic woman
that are not major issues in pregnant
women who are first diagnosed with ab-
normal glucose tolerance in pregnancy
that resolves after pregnancy. First, the
entire pregnancy is associated with ab-
normal carbohydrate metabolism, not
just the second half. The second problem
is related to the rate of congenital malfor-
mations of newborns from these pregnant
women. The third is concerned with un-
diagnosed diabetic retinopathy.
In our Japanese cohort, we observed
the results of 75-g oral glucose tolerance
tests (OGTTs) (Japan criteria: two or more
values above fasting glucose 100 mg/dl,
1-h glucose 180 mg/dl, and 2-h glucose
150 mg/dl) for 1,416 pregnant women
who had risk factors for GDM. We found
the frequency of GDM in the first trimes-
ter is the highest (33/250 [13.2%]), fol-
lowed by the second (32/417 [7.7%]) and
third trimesters (37/749 [4.9%]). Simi-
larly, the frequency of type 2 diabetes is
the highest in the first trimester at 6.0%,
with 2.6% in the second trimester and
1.3% in the third trimester. Thus, in
women with positive OGTT, GDM ac-
counts for 7.2% and type 2 diabetes diag-
nosed during pregnancy accounts for
2.5% of the total pregnant population. In
other words, 35% of women with a posi-
tive OGTT have type 2 diabetes diagnosed
for the first time in pregnancy.
In this cohort, the congenital malfor-
mation rate from GDM patients was 1.9%
and was no different from the rate in the
general Japanese population. In contrast,
the congenital malformation rate in in-
fants of type 2 diabetic mothers diagnosed
during pregnancy was higher than that of
children from pregestational diabetic
mothers treated during pregnancy, 12.7
vs. 4%, respectively.
There were no GDM patients with ret-
inopathy. However, the rate of back-
ground retinopathy was 12.7% and
proliferative retinopathy was 4.2% in the
type 2 diabetic women diagnosed for the
first time during pregnancy.
Similar rates and complications were
seen in a cohort of pregnant women in
Santa Barbara, California, where a total of
49,861 pregnancies occurred in our Mex-
ican-American population from 1997 to
2004. A total of 4,133 (8.3%) had a pos-
itive OGTT based on the ADA criteria (1).
However, 40% of the GDM women had
type 2 diabetes first diagnosed during
pregnancy based on our criteria: acantho-
sis nicgrans, requiring insulin before the
12th week of gestation, because they failed
to maintain goals with dietary intervention
alone (6). Five percent of the type 2 women
had retinopathy, and 7% had significant
proteinuria at time of diagnosis.
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O’Sullivan (2) defined GDM as “a
transient abnormality of glucose tolerance
during pregnancy.” We should return to
this time-honored definition. If type 2 di-
abetes is first detected during pregnancy,
then it should be named as such. Data
presented here underscores that this is a
worldwide problem. In preparation for
the November 2005 Fifth International
Gestational Diabetes Conference, it is
timely that we reconsider our definition of
GDM.
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Infancy-Onset Cystic
Fibrosis–Related
Diabetes
C ystic fibrosis is a genetic disordercharacterized by hyperviscous se-cretions and progressive obstructive
end organ damage. Common presenta-
tions include meconium ileus, recurrent
pulmonary infections, and failure to
thrive. Although cystic fibrosis–related
diabetes (CFRD) usually presents in the
2nd decade of life, it has been reported in
children as young as 2 years (1). Here we
present a 7-month-old infant who had
CFRD at the time of presentation with
cystic fibrosis.
A 7-month-old Caucasian male pre-
sented for evaluation of failure to thrive
despite adequate intake of high-calorie
formula. He was born at term but small
for gestational age (birth weight 3rd
percentile). Review of systems was signif-
icant for a chronic nonproductive cough,
three to five loose bowel movements per
day, and no history of polydipsia or poly-
uria. Random blood glucose obtained
during a hospitalization for bronchiolitis
at 4 months of age was normal. His only
medication was multivitamin solution.
At 7 months of age, his weight and
length were below the 3rd percentile.
Laboratory studies revealed sodium 134
mmol/l (135–145), glucose 119 mg/dl, al-
bumin 2.9 g/dl (3.1–4.7), and sweat chlo-
ride 105 mmol/l (0–40). A diagnosis of
cystic fibrosis was made. Cystic fibrosis
gene analysis revealed homozygous

F508 mutation.
Pancreatic elastase was 50 mcg EI/g
stool (normal 200), consistent with
exocrine insufficiency. Salt and pancre-
atic enzyme supplementations were in-
troduced. Total parenteral nutrition
(TPN) with glucose infusion rate of 9.7
mg  kg1  min1 was initiated. The in-
fant developed a marked hyperglycemia
(250–559 mg/dl), persistent despite the
discontinuation of TPN administration.
HbA1c (A1C) was 6.4% (4.0–5.9), and C-
peptide 0.6 ng/ml (0.9–4.2) with blood
glucose 215 mg/dl. GAD 65, islet cell an-
tibodies (ICA 512), human insulin anti-
bodies, and urinary ketones were
negative. Subcutaneous insulin was initi-
ated. The patient was discharged on insu-
lin (0.35 units  kg1  day1) and
pancreatic enzyme supplementations and
displayed excellent catch-up of linear
growth (Fig. 1). At 24 months of age, he
required 0.4 units  kg1  day1 of insu-
lin and had A1C of 8.7%.
While transient glucose intolerance
associated with steroid administration in
an infant with cystic fibrosis has been re-
ported (2), to our knowledge our case
Figure 1—Growth chart. Ar-
rows represent the initiation of
insulin and pancreatic enzyme
supplementation.
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represents the youngest patient with per-
manent CFRD ever described. The lack of
autoimmunity, continued insulin re-
quirements beyond the age of 18 months,
later age at diagnosis, and absence of phe-
notypic abnormalities (3) effectively ex-
clude type 1 diabetes and transient and
permanent neonatal diabetes, respectively.
In conclusion, this case expands the
clinical spectrum of CFRD and empha-
sizes the importance of aggressive nutri-
tional therapy and insulin replacement.
Although rare in this age-group, CFRD
needs to be considered in clinically unsta-
ble children with cystic fibrosis and
should be included in the differential di-
agnosis of non–type 1 diabetes of infancy.
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Use of Insulin
Glargine During
Pregnancy in Seven
Type 1 Diabetic
Women
Insulin glargine is a human insulin an-alog with an activity that results in arelatively constant concentration/time
profile over 24 h with no pronounced
peak. It is increasingly recognized to pro-
vide good glycemic control and to reduce
the risk of hypoglycemia in type 1 diabe-
tes (1). There may be a place for insulin
glargine in diabetic pregnancies in which
strict glycemic control and prevention of
hypoglycemia reduce the higher adverse
outcome risk. Despite animal studies
showing the safety and efficacy of insulin
glargine during pregnancy (2), its use in
human pregnancies is currently not rec-
ommended. There are two case reports on
the occasional use of insulin glargine dur-
ing pregnancy (3,4) and a notification of
its safety in five patients during the first
weeks of pregnancy (5). To date, there are
no reports on the use of insulin glargine
during the entire pregnancy in patients
with diabetes.
We examined the hospital files of
three outpatient pregnancy clinics in the
Netherlands and identified seven women
with type 1 diabetes who deliberately
used insulin glargine during pregnancy
while being aware of the unknown preg-
nancy risks. The women (three primipa-
rae and four multiparae) had a mean age
of 34 years (range 29–39) and a diabetes
duration of 12 years (5–8). Five patients
continued their preconceptional use of
insulin glargine during the entire preg-
nancy. Two patients converted from in-
termediate-acting NPH insulin to insulin
glargine after 15 and 27 weeks of amen-
orrhoea because of recurrent episodes of
nocturnal hypoglycemia. Glycemic con-
trol during pregnancy was excellent in six
patients (HbA1c [A1C] 5.2– 6.9%) and
suboptimal in one (A1C 6.4–8.1%), and
overall the mean A1C was 6.4%. The oc-
currence of hypoglycemia reduced in the
two patients that converted to insulin
glargine. Hypertension complicated two
pregnancies, while five were uncompli-
cated. All patients delivered at term
(37–40 weeks), three vaginally and four
by cesarean section. Seven children, mean
weight 4,180 g (2,475–4,675), were born
without congenital abnormalities and had
no neonatal complications during routine
observation at the neonatal care unit.
Insulin glargine has several potential
advantages in the glucose management of
type 1 diabetes, as illustrated by the ex-
cellent glycemic control with its use in six
of the seven women and the disappear-
ance of nocturnal hypoglycemia after
conversion in two of them. Insulin
glargine differs from human insulin by
the addition of two arginine residues to
the B-chain and a substitution of an aspar-
agine residue for a glycine at position 21
of the A-chain. This modified human in-
sulin molecule had no adverse effects on
reproduction, embryo-fetal development,
and postnatal development in rats (2).
The present observational study in seven
pregnancies puts forward the notion that
insulin glargine is a possible safe insulin
in human pregnancy.
Insulin glargine shares a similar time
course with human insulin for insulin re-
ceptor binding, despite a somewhat lower
affinity for the insulin receptor (6). In
contrast, insulin glargine has a sixfold-
higher binding affinity for IGF-1 recep-
tors, and experimental studies suggest an
increased mitogenicity on tumor cell-
lines at high doses (6). Does this justify a
ground to fear the use of insulin glargine
in human pregnancy? Only small
amounts of maternal insulin (1–5%) pass
the placenta and enter the fetal circula-
tion. This has been documented for hu-
man insulin (7) and the short-acting
insulin analog insulin lispro (8), with in-
sulin levels of (very) high magnitude. It is
most likely that the placental transfer of
insulin glargine is similar to the transfer of
human insulin and that of other insulin
analogs (7,8), although this has to be
proven conclusively. Considering the ex-
pected marginal amount of placental in-
sulin transfer, if any, the use of insulin
glargine in pregnancy is not likely to put
the fetus at risk. This, in combination
with the present observation of the use of
insulin glargine in seven human diabetic
pregnancies, justifies a large randomized
trial to establish the efficacy and safety of
insulin glargine in diabetic pregnancies.
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COMMENTS AND
RESPONSES
Reduction in
Cardiovascular
Events With
Atorvastatin in
2,532 Patients With
Type 2 Diabetes:
Anglo-Scandinavian
Cardiac Outcomes
Trial–Lipid-Lowering
Arm (ASCOT-LLA)
Response to Sever et al.
I read with interest the article by Severet al. in the May 2005 issue of DiabetesCare (1). I agree with the authors’ con-
clusion in the abstract that atorvastatin
made a significant impact in reducing car-
diovascular events in diabetic patients
without markedly elevated cholesterol.
However, I cannot agree with the au-
thors’ conclusion that “It now therefore
seems reasonable to recommend that ALL
(capitalization mine) patients with type 2
diabetes and hypertension . . . should be
routinely considered for statin therapy.”
The American Diabetes Association
Clinical Practice Recommendations (2),
published in January 2005, stated that for
lipid control, the primary goal is an LDL
level 2.6 mmol/l (100 mg/dl) and a
lower LDL cholesterol goal of 1.8
mmol/l (70 mg/dl) for diabetic patients
with overt cardiovascular disease. In
Sever et al.’s article (1), the subject’s aver-
age LDL cholesterol was 3.3 mmol/l (128
mg/dl) at the baseline and decreased to a
trough of an average of 2.08 mmol/l (80.4
mg/dl) at 2 years and an average of 2.15
mmol/l (83.1 mg/dl) at the end of the
study.
The article’s eligibility criteria in-
cluded subject cholesterol:HDL choles-
terol ratio 6 and total cholesterol 6.5
mmol/l (251 mg/dl) but did not break
them down further into different degrees
of lower cholesterol or LDL cholesterol
categories. I am drawing a distinction be-
tween what the article showed (lowering
of cardiovascular events by atorvastatin
for a certain group of patients, excluding
those with cholesterol 6.5 mmol/l [250
mg/dl], etc.) and what the authors claimed
to show that “It now therefore seems rea-
sonable to recommend that ALL (capital-
ization mine) patients with type 2
diabetes and hypertension (at least all
those 50 years of age and/or having di-
abetes for 10 years) should be routinely
considered for statin therapy.” Atorvasta-
tin may or may not be eventually found to
be useful for all levels of LDL cholesterol.
However, this article does not give an
answer as to how low a level of LDL cho-
lesterol a patient should obtain for a statin
to continue or cease to be useful. For ex-
ample, based on the article’s information,
I cannot yet say whether a 55-year-old
diabetic patient without overt cardiovas-
cular disease and LDL cholesterol of 1.8
mmol/l (70 mg/dl) will benefit from ator-
vastatin. That would have to await further
studies and cannot be answered by the
present article.
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Reduction in
Cardiovascular
Events With
Atorvastatin in
2,532 Patients With
Type 2 Diabetes:
Anglo-Scandinavian
Cardiac Outcomes
Trial–Lipid-Lowering
Arm (ASCOT-LLA)
Response to Tseng
W e agree with current recomenda-tions (1,2) that the use of statinsshould be based on absolute risk
rather than lipid levels. All those with di-
abetes and hypertension who are 50
years old and/or have had diabetes for
10 years are at 20% risk of a major
cardiovascular event in the next 10 years
and as such are above the currently rec-
ommended threshold for statin therapy
(1,2).
In the diabetic subgroup of the Heart
Protection Study (3), those allocated sim-
vastatin 40 mg who had an LDL choles-
terol 3 mmol/l at baseline did at least as
well in terms of major vascular events pre-
vented as those with higher LDL choles-
terol. Furthermore, mean levels in this
diabetic group overall fell to 1.8 mmol/l
on statin treatment. Hence, the LDL levels
of about half of the diabetic subjects fell
to 1.8 mmol/l. In the Collaborative
Atorvastatin Diabetes Study trial (4), 84%
of the diabetic patients were also hyper-
tensive, and the striking cardiovascular
benefits observed were equally large (38
and 37% reduction in the primary end
point) among those with LDL cholesterol
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3.1 mmol / l and 3.1 mmol / l ,
respectively.
These results are commensurate with
those reported for the diabetic subgroup
of ASCOT-LLA stratified by baseline total
cholesterol (28, 26, and 16% reductions
in total cardiovascular events and proce-
dures for those with baseline cholesterol
concentrations of 5.0, 5.0 to 6.0, and
6.0 mmol/l, respectively) (5).
These three datasets provide compel-
ling evidence that the benefits of statin
therapy are likely to be realized across the
full range of LDL cholesterol. For optimal
effect, statins should be targeted at those
above a given level of absolute risk rather
than above an arbitrary lipid level so that
the reductions in relative risk of cardio-
vascular events will generate sufficient
absolute benefit. The threshold for car-
diovascular risk currently recommended
is 20% over 10 years (1,2); hence, we
feel the final concluding statement of our
article (5) is fully justified and commen-
surate with best evidence.
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Self-Monitoring of
Blood Glucose in
Patients With Type 2
Diabetes Who Are
Not Using Insulin
Response to Welschen et al.
W e read the article by Welschen etal. (1) in Diabetes Care with in-terest. It systematically reviewed
the effect of self-monitoring of blood glu-
cose (SMBG) in patients with type 2 dia-
betes who are not using insulin. This
review is important and provides an an-
swer to the extensive debate about this
interesting topic.
The same authors published a sys-
tematic review on the same topic in April
2005 in the Cochrane Library (2). The
same articles were included in both re-
views. The authors performed a meta-
analysis in the review published in
Diabetes Care and concluded that there is
a 0.39% decrease in HbA1c (A1C) when
allowing SMBG. This effect should be in-
terpreted with caution because of the
methodological quality of the trials as ad-
dressed in the “Methodological issues”
section of the review. Also, in one of the
two studies in which a statistically signif-
icant decrease of A1C was found, only the
SMBG group received education (3). A
meta-analysis from Ellis et al. (4) con-
cluded that on average, the influence of
education itself on A1C is 0.32%.
However, in the Cochrane Library re-
view, the authors write “Because of differ-
ences in baseline data of the patients and
type of interventions between the studies,
it was not possible to perform either a meta-
analysis and/or subgroup or sensitivity
analyses.” In this review, they conclude
“SMBG might be effective in improving gly-
cemic control in patients with type 2 dia-
betes who are not using insulin.”
Within a few months, the authors
reach different conclusions regarding
methodology and supposed effects based
on the same set of available information.
Which is true: a clinically relevant reduc-
tion in A1C or a conclusion that SMBG
might be effective in improving glycemic
control in patients with type 2 diabetes
who are not using insulin?
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Self-Monitoring of
Blood Glucose in
Patients With Type 2
Diabetes Who Are
Not Using Insulin
Response to Welschen et al. and
Kleefstra et al.
I should take responsibility for the dif-ferences between the Cochrane Libraryanalysis and the review that appeared
in Diabetes Care (1). In the Cochrane Li-
brary analysis, no meta-analysis was done
for the reasons given in the letter written
by Kleefstra et al. (2). However, in the
initial submission to this journal, which
utilized the same approach as in the Co-
chrane Library analysis, the authors con-
cluded that the “level of available
evidence for the effect of SMBG on glyce-
mic control in patients with type 2 diabe-
tes who are not using insulin is at present
only moderate.” The decision to cite
“moderate” evidence was based on their
statement, “we did not want to depend on
statistical significance only because the
studies were rather small. Therefore, find-
ings were considered consistent if more
than one of the studies reported the same
direction of the effect on the outcome
measure.” Thus, regardless of statistical
significance in individual studies and in
the absence of a meta-analysis, studies go-
ing in the same direction could constitute
“moderate” evidence.
The reviewers of the initial manu-
script recommended rejection. However,
I obtained other opinions because I felt
that this topic was an important one for
our readership. One of the subsequent
statistical reviewers argued strongly that
there was no reason why a meta-analysis
of A1C levels could not be carried out on
the data in the randomized clinical trials
(RCTs) in spite of the fact that the initial
values were different among studies and
since initial A1C levels were similar in the
control and SMBG groups in each study.
This is the genesis of the statistically sig-
nificant difference of 0.39% in A1C levels
between the control and SMBG groups in
the six RCTs (3–8) in the recent review in
Diabetes Care (1). Statistical significance
was found in only two (6,7) of these six
RCTs, however.
I would like to point out that in one of
them, there were 48 and 40% drop-out
rates in the SMBG and control groups,
respectively (7). If the nearly half of the
SMBG group that failed to complete the
study were enriched in those who were
showing the least response, the results
could be due to self-selection. In the sec-
ond statistically significant study (6), a
difference in counseling between the two
groups does not allow the lowered A1C
levels to be ascribed to SMBG alone.
In my view, the available evidence
does not show that SMBG in diabetic pa-
tients not taking insulin leads to lower
A1C levels.
MAYER B. DAVIDSON, MD
EDITOR-IN-CHIEF
From the Charles R. Drew University, Los Angeles,
California.
Address correspondence to Mayer B. Davidson,
Clinical Trials Unit, Charles R. Drew University,
1731 E. 120th St., Los Angeles, CA 90059. E-mail:
madavids@cdrewu.edu.
© 2005 by the American Diabetes Association.
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
References
1. Welschen LMC, Bloemendal E, Nijpels G,
Dekker JM, Heine RJ, Stolman WAB,
Bouter LM: Self-monitoring of blood glu-
cose in patients with type 2 diabetes who
are not using insulin: a systematic review.
Diabetes Care 28:1510–1517, 2005
2. Kleefstra N, Houweling ST, van Balle-
gooie E, Bilo HJG: Self-monitoring of
blood glucose in patients with type 2 dia-
betes who are not using insulin (Letter).
Diabetes Care 28:2596, 2005
3. Fontbonne A, Billault B, Acosta M,
Percheron C, Varenne P, Besse A, Esch-
wege E, Monnier L, Slama G, Passa P: Is
glucose self-monitoring beneficial in non-
insulin-treated diabetic patients? Results
of a randomized comparative trial. Dia-
bete Metab 15:255–260, 1989
4. Allen BT, DeLong ER, Feussner JR: Im-
pact of glucose self-monitoring on non-
insulin-treated patients with type II
diabetes mellitus: randomized controlled
trial comparing blood and urine testing.
Diabetes Care 13:1044–1050, 1990
5. Muchmore DB, Springer J, Miller M: Self-
monitoring of blood glucose in over-
weight type 2 diabetic patients. Acta
Diabetol 31:215–219, 1994
6. Schwedes U, Siebolds M, Mertes G for the
SMBG Study Group: Meal-related struc-
tured self-monitoring of blood glucose:
effect on diabetes control in non-insulin-
treated type 2 diabetic patients. Diabetes
Care 25:1928–1932, 2002
7. Guerci B, Drouin P, Grange V, Bougneres
P, Fontaine P, Kerlan V, Passa P, Thivolet
C, Vialettes B, Charbonnel B: Self-moni-
toring of blood glucose significantly im-
proves metabolic control in patients with
type 2 diabetes mellitus: the Auto-Surveil-
lance Intervention Active (ASIA) study.
Diabete Metab 29:587–594, 2003
8. Davidson MB, Castellanos M, Kain D, Du-
ran P: The effect of self-monitoring of
blood glucose concentrations on glycated
hemoglobin levels in diabetic patients not
taking insulin: a blinded, randomized
trial. Am J Med 118:422–425, 2005
Self-Monitoring of
Blood Glucose in
Patients With Type 2
Diabetes Who Are
Not Using Insulin
Response to Kleefstra et al. and
Davidson
In response to Kleefstra et al. (1), we willtry to eliminate the confusion concern-ing the conclusions of our systematic
reviews on self-monitoring of blood glu-
cose (SMBG) in patients with type 2
diabetes who are not using insulin, pub-
lished in Diabetes Care (2) and the Coch-
rane Library (3).
In the Cochrane Library, we per-
formed a qualitative analysis, and because
of the consistency of the results of rather
heterogeneous trials, we concluded that
the level of evidence that SMBG might be
effective in improving glycemic control
was moderate. After a lengthy discussion,
we decided not to perform a meta-
analysis because of clinical heterogeneity
between the studies.
Because we considered this topic to
be very important to health care profes-
sionals in the diabetes field, we also sub-
mitted the review to Diabetes Care. The
editor also urged us to perform a meta-
analysis, as pointed out in his response
letter (4), to which we responded posi-
tively. We believed that this offered an
interesting opportunity to explore the
added value of having a quantitative sum-
mary estimate. On the basis of the meta-
analysis, we concluded that SMBG
significantly lowered HbA1c (A1C) by
0.39%, which is clinically relevant com-
pared with the control groups (5).
However, we respectfully disagree
with Davidson’s conclusion that the avail-
able evidence does not show that SMBG is
effective in decreasing A1C levels (4). We
believe that the current level of evidence is
only moderate, but the direction of the
evidence is positive. It is likely that in fu-
ture studies, this will be shown again, as
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was also suggested in the point discussion
in Diabetes Care accompanying our re-
view (6).
We explicitly mentioned in our dis-
cussion of the review in Diabetes Care that
the results of the meta-analysis should be
interpreted with caution since the meth-
odological quality of the trials was poor in
more than half of the studies and the stud-
ies were heterogeneous. This implies that
there are important limitations on the
meta-analysis.
In our two reviews, we used a differ-
ent approach to reach the same conclu-
sion: there may be a clinically relevant
effect of SMBG on A1C, although the ev-
idence for this effect is still moderate.
Both reviews give similar recommenda-
tions for research and clinical practice and
point out the need for a large randomized
controlled trial to draw final conclusions
on this important topic.
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C-Reactive Protein
for Cardiovascular
Risk Assessment in
the Metabolic
Syndrome
Response to Kholeif et al.
W e appreciate the comments ofDr. Kholeif (1) regarding the util-ity of C-reactive protein (CRP)
measurement in stratifying cardiovascu-
lar disease (CVD) risk as it relates to our
report of patients with the metabolic syn-
drome (2). While our data must be inter-
preted cautiously because they are of a
cross-sectional nature, our findings are
consistent with those of Ridker et al. (3)
showing metabolic syndrome patients
with elevated CRP levels to have a less
optimistic prognosis than those with nor-
mal CRP levels.
We agree with Dr. Kholeif that a sin-
gle CRP measurement, given its intraindi-
vidual biological variability, is not
suitable and that the use of multiple mea-
sures would establish the certainty of a
given level. Our study relied on the single
measurement provided by the National
Health and Nutrition Examination Survey
(NHANES) study and thus did not have
duplicate measures over time. Recently,
the Centers for Disease Control (CDC)/
American Heart Association (AHA) work-
shop on markers of inflammation and
cardiovascular disease did recommend
that the mean of only two measures taken
2 weeks apart could be averaged to pro-
vide a clinically useful value (4). We also
agree that high-sensitivity CRP assays are
critical for examining the range over
which CHD risk varies; our NHANES re-
port did utilize high-sensitivity CRP mea-
sures as recommended by the CDC/AHA
statement on the use of CRP in cardiovas-
cular risk stratification (5).
We agree with Dr. Kholeif that more
accurate risk assessment might be possi-
ble if CRP were regarded as a continuum
and included within Framingham risk or
other global risk algorithms modeling 10-
year risk of coronary heart disease, for
example, as Ridker et al. (5) have recom-
mended. Until this is done, however, we
feel that the CDC/AHA cut points (6) for
categorizing CRP into normal (1 mg/l),
borderline (1–3 mg/l), and high-risk (3
mg/l) levels are appropriate for stratifying
patient risk in combination with Fra-
mingham risk estimates or other risk fac-
tor information such as LDL cholesterol
levels.
We also agree with the CDC/AHA
statement regarding the appropriateness
of screening those at intermediate global
risk for CRP. Given this, many such per-
sons with metabolic syndrome would be
indicated for possible screening by CRP to
better identify their CVD risk where Fra-
mingham or other global risk algorithms
may fail to fully address risk given their
exclusion of abdominal obesity, elevated
triglycerides, and glucose intolerance. Of
note is that we have also shown that many
with metabolic syndrome have subclini-
cal atherosclerosis (defined by having sig-
nificant levels of coronary calcium)
regardless of estimated Framingham risk.
While 20% of such patients have 20%
10-year CHD risk, 40% have significant
calcium and/or 20% 10-year risk (7),
indicating the need to better identify
those at significant CVD risk beyond what
global risk assessment provides. None-
theless, we agree that more work from
clinical trials is needed to establish
whether intervention targeting “high-
risk” metabolic syndrome patients, iden-
tified either on the basis of elevated CRP
or other screening tests, effectively lowers
CVD risk.
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